TrialCardiovascular diabetology2017

Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.

Gian Paolo Fadini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.